Trial reportExpert opinion on drug metabolism & toxicology2018
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Trial report in Expert opinion on drug metabolism & toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02249871. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
Open the trial in the graphWho cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review.Drug design, development and therapy · 2024Pooled it
- Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.Clinical pharmacokinetics · 2023Trial
- Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.Cell reports. Medicine · 2021Trial
- Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective.Pharmaceutics · 2026Article
- Semaglutide - properties, action and chromatographic analysis.Journal of diabetes and metabolic disorders · 2025Review
- Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.Translational and clinical pharmacology · 2025Review
- A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study.Frontiers in clinical diabetes and healthcare · 2025Article
- Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.Reviews in endocrine & metabolic disorders · 2022Review
- Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.Reviews in endocrine & metabolic disorders · 2022 · on this mapReview
- Oral Semaglutide: Dosage in Special Situations.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.Pharmaceutical research · 2022Review
- Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.Endocrine reviews · 2022Review
- Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.Clinical pharmacokinetics · 2021Article
- Advances in GLP-1 treatment: focus on oral semaglutide.Diabetology & metabolic syndrome · 2021Review
- Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?International journal of molecular sciences · 2021Review
- A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.Drugs · 2021Review
- A Review on the Efficacy and Safety of Oral Semaglutide.Drugs in R&D · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the first oral glucagon-like peptide-1 analog comprises semaglutide co-formulated with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which induces a transient, localized increase in gastric pH, we have investigated whether a proton pump inhibitor affects the pharmacokinetics of oral semaglutide. RESEARCH DESIGN AND
methodsA single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects. Primary endpoints were area under the plasma concentration-time curve over 24 h for semaglutide (AUC
resultsExposure of semaglutide appeared to be slightly increased, although not statistically significantly, with oral semaglutide plus omeprazole versus oral semaglutide alone (AUC
conclusionsThere was a slight non-statistically significant increase in semaglutide exposure when oral semaglutide was administered with omeprazole, but this is not considered clinically relevant and no dose adjustment is likely to be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.